Methyleugenol
CAS 93-15-2
Methyleugenol (CAS 93-15-2) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 488.0952380952381 ug.mL-1 | 21 | - |
| - | Potency | 20308.1 nM | 10 | - |
| - | EC50 | 41275 nM | 4 | - |
| - | IC50 | 0.14125000000000001 ug.mL-1 | 4 | - |
| - | IC50 | 97400 nM | 3 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Methyleugenol used for in pharmaceutical contexts?
Methyleugenol (CAS 93-15-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Methyleugenol?
No adverse-event association or SIDER side-effect rows are rendered for Methyleugenol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Methyleugenol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Methyl Eugenol with EU status "prohibited".
What clinical phase is Methyleugenol in?
No phase 1-4 clinical development badge is rendered for Methyleugenol because the matched compound identifier rows do not contain a max-phase value.